Leo Pharma will retain thrombosis business despite goal to focus on dermatology

Although Leo Pharma’s new strategy is training its sights exclusively on the dermatology area, the company has no plans to divest its second-biggest business leg dealing with thrombosis.
Leo Pharma is struggling with a growing bottom line deficit, but according to Anders Kronborg, CFO and acting CEO until April, the ship will be turned around in 2023 | Photo: Leo Pharma / PR
Leo Pharma is struggling with a growing bottom line deficit, but according to Anders Kronborg, CFO and acting CEO until April, the ship will be turned around in 2023 | Photo: Leo Pharma / PR
by ULRICH QUISTGAARD, translated by daniel pedersen

Leo Pharma wants to become one of the world’s biggest dermatology firms by 2030. To that end, the Danish pharmaceutical firm has laid out a strategy to streamline the business and focus efforts within the dermatology area.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading